Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

Denosumab Biosimilars Impact Expected Later This Year

 
• By Mandy Jackson
  
Gains from products besides Prolia and Xgeva will grow Amgen's 2025 sales after denosumab biosimilars puts pressure on total revenue (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Scrip